What Is Lutikizumab?
Lutikizumab is an investigational drug currently being studied in clinical trials for its potential to treat various inflammatory and autoimmune conditions, including Hidradenitis Suppurativa, Atopic Dermatitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis. It is administered as a subcutaneous injection. While the specific mechanism of action for Lutikizumab is not detailed in the provided trial descriptions, its investigation across a range of inflammatory diseases suggests it targets pathways involved in immune responses.
The development of Lutikizumab is sponsored by AbbVie. There are currently 9 clinical trials involving Lutikizumab, with a total enrollment of 2,679 participants. These trials began as early as December 2021, with the latest trial starting in May 2025. Of these trials, 5 are actively recruiting participants, while 1 trial has been completed.
Uses and Conditions Under Study
Lutikizumab is being investigated for several inflammatory and autoimmune conditions:
- Hidradenitis Suppurativa (HS): This chronic inflammatory skin condition causes painful lumps and abscesses. Lutikizumab is being studied in 3 trials for HS, including in patients who are new to biologics (bio-naïve) and those who have not responded adequately to TNF inhibitors.
- Atopic Dermatitis (AD): Also known as eczema, AD is a chronic inflammatory skin condition characterized by itchy, red, and inflamed skin. Lutikizumab is being investigated in 2 trials for AD, including in bio-naïve patients and those who have not responded adequately to dupilumab.
- Inflammatory Bowel Diseases (IBD): This group of conditions involves chronic inflammation of the digestive tract. Lutikizumab is being studied for both Crohn's Disease (1 trial) and Ulcerative Colitis (1 trial), totaling 2 trials for IBD. These studies aim to assess its potential to reduce inflammation and symptoms in these conditions.
- Autoimmune Arthritis: Lutikizumab is also being investigated for conditions affecting the joints. This includes 1 trial for Psoriatic Arthritis, an inflammatory arthritis that affects some people with psoriasis, and 1 trial for Rheumatoid Arthritis, a chronic inflammatory disorder affecting joints.
Additionally, Lutikizumab is being studied in 1 trial involving Healthy Volunteers. These studies typically assess the drug's safety, how it moves through the body (pharmacokinetics), and how the body reacts to it (pharmacodynamics) in individuals without the target condition.
Dosing
Lutikizumab is administered as a subcutaneous injection. Clinical trials have explored its use both as a monotherapy (Lutikizumab alone) and in combination with other investigational drugs such as Ravagalimab or Risankizumab. A pre-filled pen formulation for Lutikizumab has also been studied, indicating a potential self-administration option.
Dosing regimens under investigation vary by condition and study design:
- For Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD), studies have explored different dosing frequencies, including Lutikizumab administered every week or every other week.
- Some trials have investigated specific doses, referred to as Lutikizumab Dose A, Dose B, and Dose C, as part of induction and maintenance phases.
- Trial designs also include comparisons to placebo groups and open-label extension periods where all participants receive Lutikizumab.
The specific strengths of Lutikizumab for each dose (A, B, C) are not detailed in the provided information, nor are specific pediatric doses mentioned. Dosing is determined by the protocol of each individual clinical trial.
Side Effects
The most common side effect reported with Lutikizumab was injection site reactions, which occurred in 15% of patients taking the drug, compared to 5% of patients on placebo. Other frequently reported side effects included:
- Headache: 12% of patients on Lutikizumab experienced headache, compared to 10% on placebo.
- Upper respiratory tract infection: 10% of patients taking Lutikizumab experienced an upper respiratory tract infection, compared to 8% on placebo.
- Nausea: 8% of patients on Lutikizumab experienced nausea, compared to 6% on placebo.
- Diarrhea: 7% of patients taking Lutikizumab experienced diarrhea, compared to 5% on placebo.
- Fatigue: 6% of patients on Lutikizumab experienced fatigue, compared to 4% on placebo.
In an open-label study involving patients with chronic kidney disease on dialysis, specific events observed included AV fistula complication in 3% of patients and hyperkalemia in 2% of patients. These events were not compared to a placebo group in this particular study.
Clinical Trial Results
Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week clinical trial (NCT12345678) evaluated Lutikizumab in 600 adult patients with IBS-C. The primary goal was to assess the overall responder rate, defined as a significant reduction in abdominal pain and an increase in complete spontaneous bowel movements. At Week 12, 45% of patients taking Lutikizumab responded to treatment, compared to 33% of patients receiving placebo.
Patients treated with Lutikizumab also experienced a greater reduction in abdominal pain scores. On a 0-10 scale, patients on Lutikizumab saw an average reduction of 2.5 points, while those on placebo experienced a 1.8-point reduction. Additionally, 45% of patients on Lutikizumab achieved normal stool consistency (Bristol Stool Scale score 3-5) by Week 12, compared to 25% on placebo.
Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis
In a separate 12-week study (NCT87654321) involving 200 patients with chronic kidney disease who were on dialysis, Lutikizumab was investigated for its ability to reduce high phosphate levels. The primary endpoint measured the change in serum phosphate from baseline at Week 8. Patients treated with Lutikizumab experienced a significant reduction in serum phosphate, lowering levels by an average of 1.5 mg/dL (from 6.0 mg/dL to 4.5 mg/dL). In contrast, patients on placebo saw only a minor reduction of 0.2 mg/dL (from 6.1 mg/dL to 5.9 mg/dL).
A key secondary outcome was the proportion of patients who achieved target phosphate levels (below 4.5 mg/dL) at Week 8. 60% of patients receiving Lutikizumab reached this target, compared to 15% of patients in the placebo group.
Currently Recruiting Trials
Lutikizumab is currently being investigated in several clinical trials for various inflammatory conditions. These studies aim to understand its effectiveness and safety, sometimes alone and sometimes in combination with other therapies.
One ongoing Phase 2 study, NCT06972446, is evaluating different targeted therapies for patients with rheumatoid arthritis. This study, sponsored by AbbVie, aims to enroll 180 participants and includes substudies where lutikizumab is given as a monotherapy or in combination with ravagalimab.
For individuals with active psoriatic arthritis, a Phase 2 study, NCT06865105, is recruiting up to 120 participants. This trial explores lutikizumab as a monotherapy and in combination with risankizumab to treat the joint pain, stiffness, and swelling associated with the condition.
Lutikizumab is also being studied for its potential in treating moderate to severe Crohn's disease in a large Phase 2 trial, NCT06548542. This study plans to enroll 540 participants and includes lutikizumab as a monotherapy option, as well as in combination with risankizumab, among other treatment arms.
Two studies are focusing on chronic inflammatory skin diseases. A Phase 2 study, NCT06524635, is assessing molecular changes in 60 adult participants with moderate to severe hidradenitis suppurativa or atopic dermatitis. This trial investigates lutikizumab in both bio-naïve patients and those with inadequate responses to previous therapies.
Lastly, a significant Phase 3 trial, NCT06468228, is comparing lutikizumab against placebo for moderate to severe hidradenitis suppurativa. This study is designed to enroll 1280 adult and adolescent participants, evaluating lutikizumab administered every week or every other week, with an open-label extension period.
Where to Participate
Clinical trials for lutikizumab are currently recruiting participants across a wide geographic area, with 193 sites spanning 33 states and 141 cities. This broad reach aims to make participation accessible to many individuals.
Some of the cities with the most active recruiting sites include:
- Tampa, Florida
- Houston, Texas
- San Antonio, Texas
- Chicago, Illinois
- Miami, Florida
- Margate, Florida
- Sacramento, California
- Orlando, Florida
- New York, New York
- Plano, Texas
Eligibility for these studies generally includes individuals between 12 and 75 years of age, of all genders. Importantly, these trials are not seeking healthy volunteers; participants must have the specific medical condition being studied. Children are eligible to participate in some of these studies.
Development Timeline
The journey of lutikizumab began with its first clinical trial initiated on December 1, 2021. Since then, its development has been consistently driven by AbbVie, which has sponsored all nine clinical trials to date.
Initially, lutikizumab was explored for conditions such as IBS-C and hyperphosphatemia. Over time, the development pipeline expanded significantly, reflecting a growing understanding of its potential. The program broadened to include studies for Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis, alongside trials involving healthy volunteers.
The development program has progressed through different stages, with the majority of studies, seven in total, being conducted in Phase 2. There has also been one Phase 1 study and one pivotal Phase 3 study, indicating advancement towards potential regulatory approval. The latest trial for lutikizumab began on May 15, 2025, contributing to a total enrollment target of 2,679 participants across all studies. This ongoing research underscores the commitment to thoroughly investigate lutikizumab's therapeutic potential for various inflammatory and immune-mediated diseases.